Compare Cisco Systems Inc (CSCO) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cisco Systems Inc vs Summit Therapeutics Inc — how do they compare? Cisco Systems Inc trades at $117.17 (market cap $452.96B), while Summit Therapeutics Inc trades at $17.38 (market cap $13.71B). The key difference: Cisco Systems Inc is far larger — about 33× Summit Therapeutics Inc's market cap, and Cisco Systems Inc pays a 1.46% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cisco Systems Inc for 86 Days and Summit Therapeutics Inc for 16 Days on average.
| CSCO | SMMT | |
|---|---|---|
Market Cap | $452.96B | $13.71B |
Volume | 12,951,578 | 6,173,057 |
Sector | Technology | Health |
52-Week High | $130.00 | $26.38 |
52-Week Low | $67.46 | $12.43 |
Typical Hold Time | 86 Days | 16 Days |
Enterprise Value | $466.58B | $13.04B |
Dividend Yield | 1.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cisco Systems (CSCO) trades at $117.39, down 0.47% on the day, with a bullish technical signal from moving averages but overbought short-term RSI. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.22, and revenue growth is supported by AI-driven networking demand. Valuation ratios are elevated with a P/E of 34.5, while profitability remains robust with a net income margin of 20.95%.
The outlook is positive given AI infrastructure growth and consistent earnings beats, but high valuation and competitive pressures pose risks. Analyst consensus is bullish with a $129.77 price target, implying potential upside. Key risks include execution challenges in integrating AI innovations and macroeconomic sensitivity.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
